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time is high. Further research with a control group is
needed to determine costs specifically attributed to BTP.
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As pharmaceutical care progresses, pharmacists must con-
tinue to develop their qualitative and quantitative assess-
ment skills. Quality of life (QoL) assessment represents an
important part of the overall outcome evaluation in the
management of depressed patients. OBJECTIVE: The pur-
pose of this prospective study was to document the QoL
reported to community pharmacists by treated ambulatory
depressed patients. METHODS: Pharmacists collected de-
mographic, antidepressant, and SF-36 questionnaire data,
and verified each patient’s antidepressant treatment for at
least three consecutive months. Most patients received their
antidepressant drug as their only medication. RESULTS:
Fifty-seven patients completed SF-36 questionnaires and de-
mographic data forms under the supervision of their com-
munity pharmacists. Thirty-five patients were treated with
SSRI’s while 22 were treated with Non-SSRI’s. Patients re-
ceiving Non-SSRI’s were eight years older on average than
those receiving SSRI’s (P  0.05). Patients receiving SSRI’s
scored statistically higher on five SF-36 Scale scores, in-
cluding physical functioning, role-physical, general health,
vitality, and mental health. Physical component summary
(PCS) scores were statistically higher for SSRI patients
than Non-SSRI patients, with scores of 49.95 and 39.39,
respectively (P  0.05). Mental component summary
(MCS) scores were similar for SSRI patients and Non-
SSRI patients, with scores of 45.02 and 42.48, respec-
tively. CONCLUSION: Non-SSRI patients demonstrated
a statistically poorer QoL in the PCS and related Scale
scores, a finding which is consistent with their older
mean age. These data support the avoidance of Non-SSRI
therapy in older depressed patients. These data also com-
pare favorably with the findings documented in medical
care settings, demonstrating the utility of the SF-36 by
community pharmacists in their usual practice settings.
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Many health-related quality of life instruments are not
useful in clinical practice because of their length and
scoring algorithms. The brief Quality of Life With Mi-
graine (QOLWM) questionnaire was designed as a
screening tool for general use by migraineurs. OBJEC-
TIVE: To determine sensitivity to discriminate among
levels of headache frequency and severity, and medication
usage. METHODS: The previously validated QOLWM
asks about the frequency and impact of seven problem
areas. Migraineurs participated in a web-based survey of
demographic and headache characteristics, use of pre-
scription and non-prescription headache medications,
and quality of life. ANOVA analyses included 994 re-
spondents who completed all QOLWM items. RESULTS:
Patients experiencing a high frequency of headaches (P 
0.0001) and days with severe headaches (P  0.0003) in
the previous month also had significantly lower quality
of life (higher QOLWM Total Scores) than patients re-
porting less frequent and severe episodes. Compared to
patients without such problems, those reporting nausea
(P  0.016), distress with activity (P  0.0001) or light
(P  0.01) had lower QOLWM scores. Patients taking
prescription medications daily (P  0.0001), or who
took prescription drugs at the beginning or during a
headache (P  0.01) also had lower QOLWM scores
than patients who did not use prescription medications.
Patients who took medications only at the headache on-
set (P  0.0001) had lower QOLWM scores than people
who took medication daily. CONCLUSIONS: These
data suggest that the QOLWM could discriminate among
patients with varying headache severity and medication
usage. The QOLWM could be useful for headache assess-
ment in clinical practice.
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Instrument-based scores are often used as outcome mea-
sures. However, little is known about what changes in
scores mean in terms of a clinical assessment of improve-
ment or deterioration. OBJECTIVE: The purpose of this
study was to determine how much change in standard
symptom and HRQOL instrument scores represents a
clinically detectable improvement or deterioration for
schizophrenia patients. METHODS: The VA Coopera-
tive Study of Clozapine in Refractory Schizophrenia eval-
uated 423 patients with clozapine or haloperidol. Symp-
toms (PANSS) and quality of life (QLS) scales were
competed at baseline, 1.5, 3, 6, and 12 months. Changes
were calculated as percentage improvement and as
changes in a mean 7-point item scale based on clinicians’
ratings of patient status compared to baseline. RE-
SULTS: Based on clinician-assessed improvements from
baseline, PANSS scores improved by 21%; QLS scores by
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26% when patients were rated as “improved,” and 45%,
50%, respectively when rated as “much better.” Mean
7-point item scores improved by 0.46 points PANSS,
0.23 points QLS for “improved” patients, and by 0.88,
0.92, respectively for “much better” patients. Minimal
changes were seen for all items when patients were rated
as “unchanged.” The relationship between clinician rat-
ings and score changes was stable over multiple assess-
ments in this large sample. CONCLUSION: These data
describe the amount of change that represents clinically
important improvement related to treatment based on
commonly used symptom and QOL scales. Planning
sample sizes for clinical trials can be based on percentage
change in scores or mean item scores to aid clinicians and
researchers in understanding meaningful treatment ef-
fects.
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OBJECTIVES: The MSQ (Migraine Specific Quality of
Life Questionnaire) measures migraine-related quality of
life in three dimensions [Role Restrictive (RR), Role Pre-
ventive (RP), and Emotional Function (EF)]. The objec-
tive of this analysis was to compare the psychometric
properties of the Finnish (FN), Dutch (HD), Hungarian
(HG), Spanish (SP), and UK English translations with the
original US English version of the MSQ. METHODS:
One hundred and ninety-eight Finns, 127 Dutch, 169
Hungarians, 116 New Zealanders, and 169 Spaniards,
participated in a multinational migraine clinical trial in
which the MSQ was completed at baseline and after a 3-
month treatment period with customary therapy or
naratriptan 2.5 mg. The distribution of item responses,
item-discriminant validity and scale-level reliability for
the MSQ translations were examined and compared to
the previously published US English version results. RE-
SULTS: The distribution of responses for each item was
negatively skewed for all translations. The full range of
the response categories was used by migraineurs from all
countries except for the FN version in the clinical trial.
Every translation of the MSQ possessed item-scale corre-
lations that were higher for the hypothesized scale com-
pared to competing scales. Similar to the US English ver-
sion results, baseline Cronbach’s Alpha coefficients for
the three MSQ dimensions were greater than 0.82 for all
translations. The MSQ translations were sensitive to de-
tect intervention differences after 3 months of naratrip-
tan treatment for migraines. CONCLUSIONS: The MSQ
translations have demonstrated item-level discriminant
validity, reliability, and sensitivity to detect treatment
changes in quality of life and has cross-cultural empirical
validity. The MSQ is an effective tool in assessing mi-
graine-related quality of life across different cultures.
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OBJECTIVE: To evaluate the impact of schizophrenia
versus other chronic conditions on health-related quality
of life (HRQL). METHODS: Patients who were admitted
to a psychiatric inpatient unit at one of the 100 acute
care hospitals using the CQIsm Outcomes Measurement
System were administered the SF-36 health status survey.
All patients with a discharge diagnosis of schizophrenia
who completed the SF-36 and were admitted to adult
(n  233) or geropsychiatric (n  380) inpatient units
were selected. Randomly generated observations were
drawn from general US population SF-36 data to con-
struct two general population cohorts matching the adult
and geriatric schizophrenia samples, respectively, in dis-
tribution of age and gender. Adult and geriatric schizo-
phrenic cohorts were compared to their corresponding
matched general population cohort on each of the eight
SF-36 domains. Comparisons were also made to three
disease cohorts: Hypertension, Congestive Heart Failure
(CHF), and Diabetes. Independent sample t-tests were
used to evaluate differences between the groups. RE-
SULTS: Schizophrenic patients from both adult and geri-
atric groups had significantly lower scores (P  .001) on
virtually all mental and physical HRQL domains when
compared to the general US population and to patients
with hypertension or diabetes. Both groups of schizo-
phrenics scored lower (P  .001) on mental health do-
mains when compared to CHF patients. Adult schizo-
phrenics scored higher in the physical health domains
than CHF patients (P  .05), while geriatric schizophren-
ics were similar to CHF patients in those domains. CON-
CLUSIONS: Schizophrenia’s association with lower
HRQL extends beyond mental health to physical health
status. The physical health status of schizophrenics is
more impaired than those observed in patients with dia-
betes and hypertension, and is comparable to patients
with CHF.
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